Cytokinetics, Incorporated (CYTK)

Check out top investors' recommendation for CYTK
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
20.67
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company’s drug candidates in clinical development include Tirasemtiv, a skeletal muscle troponin activator, which is in Phase II clinical trials; and CK-2127107, a pre-clinical skeletal sarcomere activator for treating diseases or medical conditions associated with skeletal muscle weakness or wasting. It is also involved in developing omecamtiv mecarbil, a cardiac muscle myosin activator for the treatment of heart failure that is in Phase I and IIb clinical trials; and conducting earlier-stage research directed to other compounds to modulate muscle contractility and other muscle functions, such as growth, energetics, and metabolism. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Matthew Harrison UBS Buy   Nov 22, '17     17.00  Nov 22, '18  N/A 
Charles Duncan Piper Jaffray Buy   Nov 21, '17     18.00  Nov 21, '18  N/A 
Jason Butler JMP Securities Buy   Nov 21, '17     13.00  Nov 21, '18  N/A 
Chad Messer Needham & Company Buy   Oct 27, '17     22.00  Oct 27, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 27, '17     26.00  Oct 27, '18  N/A 
Mara Goldstein Cantor Fitzgerald Buy   Oct 26, '17     21.00  Oct 26, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 20, '17     26.00  Sep 20, '18  N/A 
Mara Goldstein Cantor Fitzgerald Buy   Sep 18, '17     21.00  Sep 18, '18  N/A 
Alan Carr Needham & Company Buy   Sep 15, '17     22.00  Sep 15, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 03, '17     26.00  Aug 03, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Aug 03, '17     19.00  Aug 03, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Feb 21, '17       Feb 21, '18  N/A 
Jason Butler JMP Securities Buy   Dec 01, '16       Dec 01, '17  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 28, '16     22.00  Oct 28, '17  N/A 
Ritu Baral Canaccord Genuity Buy   Oct 28, '16     16.00  Oct 28, '17  N/A 
Simos Simeonidis Cowen And Company Buy   Oct 05, '16     16.00  Oct 05, '17  N/A 
Ritu Baral Canaccord Genuity Buy   Feb 17, '16   6.79  16.00  Feb 17, '17  66.42% 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 19, '16   8.16  22.00  Jan 19, '17  34.80% 
Charles Duncan Piper Jaffray Buy   Dec 16, '15   11.65  24.00  Dec 16, '16  -0.86% 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 23, '15   6.84  18.00  Oct 23, '16  34.36% 
< previous123